Introduction
Lung cancer is the commonest cause of neoplastic death in the developed world. Small cell lung cancer (SCLC) constitutes 25% of all pulmonary malignancies and, despite initial sensitivity to treatment, the overall ®ve year survival is less than 5% (Smyth et al., 1986) .
Consequently, novel therapeutic strategies are urgently required and these will most likely arise from a better understanding of the disease biology. Multiple Ca 2+ -mobilizing neuropeptides have been identi®ed as autocrine/paracrine growth factors for SCLC (Bunn et al., 1990; Seckl and Rozengurt, 1998; Sethi and Rozengurt, 1991) . In contrast, apart from stem cell factor (Hibi et al., 1991; Krystal et al., 1996; Seckl et al., 1994) , hepatocyte growth factor (Seckl et al., 1994) and insulin-like growth factor (Macaulay et al., 1990) , polypeptide growth factors have not been thought to play a major role in driving SCLC cell proliferation. Strikingly, although ®broblast growth factor-2 (FGF-2) is abundantly expressed in adult human lungs (CordonCardo et al., 1990) , there have been no previous reports examining the biological eects of this polypeptide growth factor in SCLC.
Among the twenty structurally related polypeptides (FGF-1 to 20) that constitute the mammalian FGF family, FGF-2 is one of the most extensively studied (Miyake et al., 1998; Szebenyi and Fallon, 1999) . This growth factor plays a key role in diverse biological processes, which are of particular interest to cancer biology, including proliferation, dierentiation, migration, survival and neovascularization (Bikfalvi et al., 1997) . FGFs elicit their biological activities by binding to high anity FGF receptor (FGFR) tyrosine kinases in the presence of heparin or heparan sulfate. There are four FGFRs (FGFR1 ± 4), with multiple additional isoforms due to alternative mRNA splicing, but only FGFR1 and FGFR2 isoforms appear to have high anity for FGF-2 (Chellaiah et al., 1994; Mansukhani et al., 1992; Ornitz et al., 1996; Ron et al., 1993; Werner et al., 1992) . FGFR1 has often been used as a model to understand the activation of FGFRs as well as the early signalling events induced by FGF-2. Like most other receptor tyrosine kinases, ligand binding induces FGFR dimerization (Plotnikov et al., 1999) and transphosphorylation of the intracytoplasmic tail on several tyrosine residues (Mohammadi et al., 1996) . FGFR1 couples to the Ras/Raf/MEK/extracellular regulated kinase 1/2 (ERK1/2) pathway via an FGFR docking protein called FGFR substrate-2 (Kouhara et al., 1997) . In addition, this receptor can bind to and activate phospholipase C-g, which hydrolyses phosphatidylinositol bisphosphate into diacylglycerol and inositol trisphosphate, leading to stimulation of protein kinase C (PKC) and intracellular Ca 2+ release, respectively (Mohammadi et al., 1992; Vainikka et al., 1992) . Activation of the phosphatidylinositol 3-kinase (PI3K) has been seldomly observed downstream of FGFR1 (Kanda et al., 1997; WennstroÈ m et al., 1994; Zubilewicz et al., 2001) . Nevertheless, p70 S6 kinase a (S6K1), a downstream target of the PI3K pathway, is activated in response to FGF-2 (Bailly et al., 2000; Kanda et al., 1997; Zubilewicz et al., 2001) .
Recently, a novel S6K isoform, p70 S6 kinase b (S6K2), has been cloned (Gout et al., 1998; Lee-Frumen et al., 1999; Shima et al., 1998) . Both S6K1 and 2 phosphorylate the ribosomal S6 protein in vitro. This phosphorylation event increases the translation of mRNAs containing 5'-oligopyrimidine tracts in vivo permitting de novo protein synthesis necessary for growth and proliferation (Dufner and Thomas, 1999) . S6K1 and 2 are highly homologous, but dier substantially in their N-and C-terminal domains, two regions involved in the modulation of S6K1 activity. Both isoforms are thought to be regulated by signalling from PI3K and the mammalian target of rapamycin (mTOR) (Gout et al., 1998; Koh et al., 1999; Lee-Frumen et al., 1999; Shima et al., 1998) . Nevertheless, there is some evidence that S6K2 is relatively less sensitive to inhibitors of PI3K and mTOR than S6K1 (Gout et al., 1998) . This suggests that the regulation and functions of S6K1 and 2 may dier. Currently, nothing is known about the presence or the control of S6K2 in SCLC cells.
Here, we show that activation of S6K1 by FGF-2 is necessary for SCLC cell proliferation. Nevertheless, additional stimulation of the MEK/ERK pathway correlated with S6K2 activation and increased sensitivity to the growth factor. S6K1 activation was necessary and ERK1/2 signalling contributed to proliferation. Strikingly, both S6K1 and 2 were massively over-expressed in all SCLC cell lines examined compared to primary cultures of normal human pneumocytes. Collectively, our results suggest that both kinases may play an important role in the aberrant growth response of this cancer.
Results

FGF-2 induces clonogenic growth and proliferation of SCLC cells
FGF-2 is a well-documented mitogen in various cell systems. However, its role in the biology of SCLC has not previously been examined. Malignant and transformed cells are often capable of anchorage-independent growth and form colonies in semi-solid medium. In SCLC, in vitro clonogenic growth correlates with the invasiveness of tumours in patients (Carney et al., 1980) . Therefore, we performed clonogenic assays as a read-out for the eects of FGF-2 on the tumorigenicity of SCLC cells. Addition of this growth factor stimulated a dose-dependent increase in the number of colonies formed by H-510 SCLC cells with a peak eect obtained at 0.1 ng/ml FGF-2 ( Figure 1a , left panel). In contrast, 10-fold higher concentrations of FGF-2 were required to induce maximal growth of H-69 SCLC cells (Figure 1a , right panel). Tumorigenicity is a complex phenomenon that can result from increased cell proliferation. To test whether FGF-2 is a mitogen for SCLC cells, we performed liquid culture assays. These showed that the proliferation rate of H-510 cell was dramatically increased in the presence of 0.1 ng/ml FGF-2, as compared with unstimulated controls (Figure 1b, left panel) . In H-69 cells, while 0.1 ng/ml FGF-2 induced some proliferation, similar mitogenesis to that seen in H-510 cells was only achieved at 10-fold higher FGF-2 concentrations (Figure 1b, right panel) . These results demonstrate that, despite FGF-2 inducing the proliferation of both cell lines, lower concentrations of this growth factor are required in H-510, as compared to H-69 SCLC cells.
FGFR1 is expressed and activated by FGF-2 in both H-510 and H-69 SCLC cells FGFR1 is one of the principal receptors for FGF-2 and has been more frequently studied than any other FGFR isoform for its downstream signalling. Consequently, we examined whether H-510 and H-69 SCLC cells express FGFR1. Western blot analysis demon- strated that these cells expressed similar levels of FGFR1 protein (Figure 2a ). Some isoforms of FGFR1 are kinase defective and are therefore not activated by FGF-2 (Shi et al., 1993) . However, in both SCLC cell lines, transphosphorylation of FGFR1 was increased upon addition of FGF-2 (Figure 2b ). Thus, SCLC cells express a functional FGFR1.
FGF-2 induces ERK1/2 signalling in H-510, but not H-69 SCLC cells FGF-2 is known to activate ERK1/2 in other cell systems. These kinases require dual phosphorylation on Thr/Tyr sites for their activation, a phenomenon that can be monitored by Western blotting with a biphosphospeci®c antibody. Using this approach, we show that FGF-2 induced a dose-dependent increase in ERK1/2 phosphorylation with a maximum obtained at 0.1 ng/ml in H-510 cells (Figure 3a , left panel). This eect was transient, reaching a peak at 5 min, and returning to control levels between 10 ± 30 min ( Figure  3b left panel). In marked contrast, FGF-2 failed to stimulate ERK1/2 over a broad concentration and time range in H-69 cells (Figure 3a , b, right panels). However, ERK1/2 was present in these cells and could be stimulated by either phorbol ester or stem cell factor (Figure 3a , b, right panels). Similarly, immune complex kinase assays demonstrated that FGF-2 induced ERK1/2 activation in H-510, but not in H-69 cells (data not shown). We also examined the phosphorylation of MEK1/2, the dual speci®city kinase responsible for ERK1/2 activation. Like for ERK1/2, the activation of MEK can be assessed using phospho-speci®c antibodies. Figure 3c demonstrates that FGF-2 stimulated phosphorylation of MEK in H-510, but not in H-69 SCLC cells. Thus FGF-2 induces MEK/ ERK signalling in H-510, but not H-69 SCLC cells.
FGF-2 induces S6K1 activation in both SCLC cell lines but only activates S6K2 in H-510 cells
The absence of MEK/ERK signalling in the H-69 SCLC cells prompted us to identify other early signalling events which could mediate mitogenesis in these cells. S6K1 is well known to be crucial for proliferation induced by many growth factors and has been shown to be activated by FGF-2 (Bailly et al., 2000; Kanda et al., 1997) . Addition of FGF-2, at concentrations that induced maximal proliferation, stimulated an approximately threefold increase in S6K1 activity, as determined by immune complex kinase assays in both SCLC cell lines (Figure 4a ). The activation of S6K1 involves phosphorylation on multiple Ser/Thr sites, leading to retardation in its electrophoretic mobility (Chou and Blenis, 1995; Chung et al., 1992; Ferrari and Thomas, 1994) . Two of these phosphorylation sites are directly linked to activation of the enzyme: Thr-389 in the carboxyterminal region and Thr-229 in the activation loop (Alessi et al., 1998; Pullen et al., 1998) . In order to substantiate the results obtained by immune complex kinase assay, we used band shift detection and phospho-speci®c antibodies to the Thr-389 and Thr-229 sites. As shown in Figure 4b , FGF-2 induced the appearance of slower migrating forms of S6K1 and the phosphorylation of Thr 389 and 229 in both SCLC cell lines.
Recently, a new isoform of S6K has been identi®ed and termed S6K2 (Gout et al., 1998; Lee-Frumen et al., 1999; Shima et al., 1998) . The presence of S6K2 in SCLC cells, or its regulation by FGF-2 has not been previously documented. Here, we show that S6K2 was detected in both H-69 and H-510 cells (Figures 4b and  7) . Nevertheless, in contrast to S6K1, FGF-2 induced activation of S6K2 only in H-510 cells (Figure 4a ). This activation appeared to correlate with the phosphorylation of Thr-228 (equivalent to Thr-229 in S6K1), while Thr-388 (equivalent to Thr-389 in S6K1) was constitutively phosphorylated. In H-69 cells, where FGF-2 failed to induce S6K2 activation (Figure 4a ), no phosphorylation of these sites was observed ( Figure  4b ). Thus, FGF-2 induces S6K1 activation in both SCLC cell lines, but S6K2 is only activated in H-510 cells, where FGF-2 couples to MEK/ERK signalling.
MEK/ERK signalling contributes to S6K2, but not S6K1 activation by FGF-2
In view of the above observations, we investigated the existence of a possible cross-talk between the MEK/ ERK and S6K pathways that could account for S6K2 activation. Indeed, uncoupling of FGFRs from MEK/ ERK signalling in H-69 cells might explain the failure of FGF-2 to activate S6K2 in these cells. A prediction of this hypothesis would be that inhibition of MEK in H-510 cells should block the activation of S6K2 by FGF-2. Consequently, we tested the eect of the welldescribed and selective MEK inhibitor, PD098059, on FGF-2-induced S6K1 and 2 activation in these cells. Dose response experiments showed that 25 mM PD098059 was the minimum concentration required to optimally inhibit ERK1/2 activation induced by FGF-2 (data not shown). Figure 5a demonstrates that 25 mM PD098059 had no eect on S6K1 activation by FGF-2. In marked contrast, this concentration reduced S6K2 activation by 53+1% (mean+s.e. n=3). Similar results were obtained using the structurally distinct MEK inhibitor, U0126 (data not shown). These results support the hypothesis that MEK/ERK signalling contributes to S6K2 activation downstream of FGF-2. However, the fact that complete MEK inhibition fails to fully block S6K2 activation suggests that additional pathway(s) may regulate this kinase.
The mammalian target of rapamycin (mTOR) is known to control S6K1 activation by FGF-2 and is thought to be similarly involved in S6K2 activation. Rapamycin inhibits mTOR and previous work has shown that 10 ng/ml of this drug optimally blocks S6K1 phosphorylation in SCLC cells (Seuerlein and Rozengurt, 1996) . Indeed, we found that this concentration of rapamycin completely blocked FGF-2-induced S6K1 activation, as determined by immune complex kinase assay. Interestingly, the same concentration of rapamycin had no eect on S6K2 activation (Figure 5a ). Therefore, we performed dose response experiments to determine whether higher concentrations of rapamycin could block S6K2. Figure 4b demonstrates that the IC 50s of rapamycin for S6K1 and 2 are very dierent (1.5 and 65 ng/ml respectively). Moreover, even at 100 ng/ml rapamycin, S6K2 was only partially inhibited. These results provide evidence that the regulatory pathways controlling S6K1 and 2 activation are distinct.
The inhibition pattern observed in Figure 5b for S6K2 did not suggest that rapamycin exerted its eect with a speci®city similar to the inhibition of S6K1 activity. Therefore, we investigated whether the eect of high rapamycin concentrations (above 50 ng/ml) on S6K2 activation might be due to inhibition of MEK/ ERK signalling. Low rapamycin concentrations (1 ± 10 ng/ml), did not signi®cantly aect FGF-2-induced ERK1/2 phosphorylation ( Figure 5c ). In contrast, 100 ng/ml rapamycin partially inhibited ERK1/2 phosphorylation induced by FGF-2 ( Figure  5c ), suggesting that the eect of rapamycin on S6K2 activation correlates with the inhibition of ERK signalling. Together, our data demonstrate that the activation of S6K2 by FGF-2 is probably independent of mTOR and is regulated by MEK/ERK signalling.
FGF-2-induced S6K1 and 2 activation is not mediated by PI3K signalling
Many growth factors activate S6K1 via a PI3K-dependent pathway (Dufner and Thomas, 1999) , and S6K2 activation is thought to occur in a similar fashion. Nevertheless, although p85a was present and PI3K could be activated by serum, PI3K activity was not increased in anti-p85a immunoprecipitates from FGF-2-stimulated H-510 cells (Figure 6a ). FGF-2 similarly failed to induce PI3K activity in antiphosphotyrosine immunoprecipitates (data not shown). Lysates from H-510 and H-69 cells stimulated for 5 min with 0.1 and 1 ng/ml FGF-2, respectively, were analysed by SDS ± PAGE for the presence of biphospho-MEK1/2. PDB stimulation (400 ng/ml, 5 min) was used as a positive control. Each blot is representative of at least three independent experiments. Lamin B detection was used as a control for protein loading This inability of FGF-2 to stimulate PI3K has been previously reported in other (Kanda et al., 1997; WennstroÈ m et al., 1994) but not all (Zubilewicz et al., 2001 ) cell systems. In order to con®rm our ®ndings, we examined a downstream target of the PI3K pathway, protein kinase B (PKB). Activation of PKB relies on the phosphorylation of Thr-308 and Ser-473 and phosphospeci®c antibodies to the latter site have frequently been used as a simple and sensitive readout for PI3K activity (WennstroÈ m and Downward, 1999) . Despite PKB being present in H-510 cells (Figure 6b , upper panel), we were unable to detect Ser-473 phosphorylation in response to FGF-2. This was not a consequence of either a lack of sensitivity of the phosphospeci®c antibody or low protein loading, as samples from COS cells run in parallel showed EGFinduced PKB phosphorylation, despite lower total levels of this kinase. Taken together, these results show that FGF-2 does not activate PI3K in SCLC cells, and thus PI3K signalling cannot account for FGF-2-induced activation of S6K1 or S6K2.
Role of MEK and mTOR in FGF-2 induced proliferation
We next assessed the relative contributions of the MEK/ERK and mTOR/S6K1 pathways to FGF-2-induced proliferation in SCLC cells. At a concentration of FGF-2 which induced maximal proliferation and MEK/ERK signalling in H-510 cells, MEK inhibition by PD098059 completely blocked proliferation ( Figure  7) . Moreover, PD098059 treatment slightly but signi®cantly reduced the cell count in unstimulated H-510 cells, as compared to untreated controls. However, in H-69 cells, where FGF-2 did not couple to MEK/ERK signalling, MEK inhibition failed to block FGF-2-stimulated or unstimulated cell proliferation. Thus, MEK/ERK signalling is essential for mitogenesis in H-510, but not H-69 SCLC cells. In contrast, low concentrations of rapamycin, which selectively inhibit S6K1 activation, completely prevented FGF-2-induced proliferation in both H-510 and H-69 cells (Figure 7 ). These data indicate that S6K1 is necessary for FGF-2-mediated proliferation of both SCLC cell lines.
S6K1 and 2, but not ERK1/2 are up-regulated in SCLC cells
The notion that S6K1 plays a crucial role in SCLC tumorigenesis would be supported if this kinase was commonly over-expressed in SCLC compared to normal human lung epithelial cells. A search of the expressed sequence tagged (EST) database for S6K1 and 2 revealed that both these kinases are overrepresented in all SCLC cell lines examined. We have recently developed techniques to purify primary cultures of human type II lung epithelial cells, which . Cell lysates were analysed by SDS ± PAGE and Western blotting with a biphosphospeci®c antibody to ERK1/2. The results shown are representative of at least three independent experiments. Lamin B was used as a control for protein loading are believed to be one of the precursors of all lung cancers (Belinsky et al., 1992; Gazdar et al., 1981; Risse-Hackl et al., 1998; Ten Have-Opbroek et al., 1997) . The comparative Western blot analysis of type II pneumocyte samples from two dierent donors and a panel of eight SCLC cell lines at low passage revealed a marked up-regulation of both S6K1 and 2 isoforms in all SCLC cells examined (Figure 8a) . Comparable analysis for actin demonstrated that this was not a consequence of unequal protein loading. Furthermore, the increase in S6K1 and 2 was not due to a general up-regulation of signalling molecules in SCLC cells, since ERK1/2 protein levels did not signi®cantly dier between the type II pneumocytes and the cancer cell lines (Figure 8a ). Therefore, both S6K1 and 2 are selectively over-expressed in SCLC cells. Nevertheless, increased S6K expression does not necessarily correlate with increased activity which may be required for these enzymes to contribute to tumorigenesis. Consequently, we investigated the phosphorylation status of T389 and T228 which best matched activation of S6K1 and S6K2, respectively (Figure 4b ). We found that the basal phosphorylation of both S6K1 and 2 were increased in all SCLC cell lines compared to type II pneumocytes (Figure 8b ). Our results suggest that both S6K1 and 2 may play a key role in the uncontrolled proliferative potential of these tumour cells.
Discussion
The involvement of neuropeptide growth factors in SCLC is well documented (Bunn et al., 1990; Seckl and Rozengurt, 1998; Sethi and Rozengurt, 1991) . In contrast, the role of polypeptide growth factors in the biology of this malignancy is poorly understood. Here, we provide the ®rst evidence that FGF-2 stimulates SCLC growth and that this eect can partly be attributed to cell proliferation, as demonstrated by liquid culture assays. This is of relevance, as this growth factor is physiologically present in the lung and could therefore act locally on tumour development (CordonCardo et al., 1990) . Moreover, optimal SCLC growth was obtained at concentrations of FGF-2 often found in the serum of patients with various types of lung carcinomas (Fujimoto et al., 1991; Linder et al., 1998) . 2) and 8 SCLC cell lines (lane 3 ± 10, HC-33, H-69, H-209, H-510, H-524, H1045, H-1622, H-2171, respectively) were analysed either by SDS ± PAGE and Western blotting for S6K1, S6K2, ERK1/2 and actin protein expression levels (a) or by immunoprecipitating S6K1 and 2 followed by Western blotting for T389 and T228, respectively (b). Results shown are representative of three independent experiments FGF-2 binds to split-tyrosine kinase receptors that activate well-documented early signalling events including the protein kinases ERK1/2 and S6K (Bailly et al., 2000; Gardner and Johnson, 1996; Kanda et al., 1997; Zubilewicz et al., 2001 ). As we were aiming to investigate which of these signalling events were involved in FGF-2-mediated SCLC cell proliferation, we found that various SCLC cell lines did not respond equally to this growth factor. Indeed, while S6K activation occurred in all SCLC cell lines tested ( Figure  4 and data not shown), FGF-2 stimulated ERK1/2 in only half of these (Figure 3 and data not shown). This suggested that S6K was the major regulator of this growth-promoting eect, a hypothesis con®rmed by the inhibition of FGF-2-mediated cell proliferation by low concentrations of the mTOR inhibitor, rapamycin. Nevertheless, in H-510 cells, where MEK/ERK activation occurred, inhibition of this signalling pathway by PD098059 blocked FGF-2-induced mitogenesis as eciently as rapamycin. Therefore, while ERK activation is not an absolute requirement for SCLC proliferation, it appears to provide additional signals to the S6K pathway for cell proliferation in response to FGF-2.
It is worth noticing that PD098059 reduced the cell count for the unstimulated H-510 cells in liquid culture assays. This eect was even more pronounced in clonogenic growth assays where PD098059 decreased control colony numbers by half (our unpublished observations). These results could be attributed to the action of this inhibitor on MEK, as a reduction in cell number or clonogenic growth was not observed in H-69 cells. This suggests that MEK/ERK signalling is involved in the basal proliferation of H-510 cells. An additional role for this pathway in modulating the survival of H-510 cell cannot be excluded and warrants further investigation.
To date, two isoforms of S6K have been identi®ed; S6K1 and the more recently cloned S6K2 (Gout et al., 1998; Lee-Frumen et al., 1999; Shima et al., 1998) . While S6K1 was activated in both H-510 and H-69 cells in response to FGF-2, S6K2 appeared to be activated in H-510 cells only. This discrepancy was not due to the absence of the latter isoform in H-69 cells, as Western blot analysis showed equal expression of S6K2 in both H-510 and H-69 cells (Figure 7 ). This prompted us to investigate a possible involvement of the MEK/ERK pathway in S6K2 activation. Indeed, it was recently suggested that S6K2 might be speci®cally regulated by the MEK/ERK pathway, while sharing with S6K1 similar sensitivity to rapamycin (Martin et al., 2001) . Our data partly support these ®ndings, as we con®rm that MEK inhibition leads to a reduction of S6K2 activation. However, in contrast to previous reports (Lee-Frumen et al., 1999; Shima et al., 1998) , we found that S6K2 was resistant to rapamycin, as only high concentrations of this inhibitor (50 times the IC 50 for S6K1) could reduce S6K2 activation (Gout et al., 1998 ; and the current paper). These high concentrations have been used by some previous investigators to argue in favour of S6K2 sensitivity to rapamycin (Lee-Frumen et al., 1999) . Nevertheless, we demonstrate that the selectivity of rapamycin for the S6K pathway is lost under these conditions, as the inhibitor blocked FGF-2-induced MEK (our unpublished data) and ERK1/2 phosphorylation. Therefore, the eect of rapamycin on S6K2 activation previously described by Lee-Frumen et al., may be attributed to inhibition of MEK/ERK signalling. However, the resistance of S6K2 to rapamycin is still controversial as Shima et al. (1998) described inhibition of this kinase at comparatively low rapamycin concentrations (520 ng/ml). These discrepancies may re¯ect dierences in cell signalling pathways found in the distinct cell systems used. Taken together our results provide new evidence that S6K1 and S6K2 are regulated through distinct signalling pathways in SCLC cells.
Considerable evidence exists showing that dual phosphorylation of T229 and T389 is required for full activation of S6K1 (Dufner and Thomas, 1999) . It is plausible that the regulation of S6K2 may occur through sequential phosphorylation of the corresponding Thr residues. In this model one would expect the homologous sites to be phosphorylated by the same pathways. However, our results do not necessarily support this notion. Indeed, in H-510 cells the T388 site of S6K2 is constitutively phosphorylated whereas its homologous site in S6K1 is inducible. Therefore it appears that the upstream signalling pathways required for the phosphorylation of both these sites may dier. This notion is supported by the observation that in H-69 cells while the T389 of S6K1 is inducibly phosphorylated in response to FGF-2, an equivalent regulation is not seen with S6K2. The identity of the kinases responsible is currently under investigation. Recent work has shown that NEK6 could be responsible for phosphorylation of T389 in S6K1 (Belham et al., 2001) . In contrast, the kinase regulating T388 on S6K2 is currently unknown but might be downstream of MEK/ERK signalling.
The fact that both these kinases were over-expressed and their basal phosphorylation status increased in all SCLC cell lines examined compared to normal human lung epithelial cells, supports the notion that S6K1 and S6K2 might play a crucial role in the malignant process of this tumour. The function of S6K2 is currently unknown. S6K1 is known to regulate cap-dependent protein synthesis (Dufner and Thomas, 1999) and the overall homology between S6K1 and 2 would suggest that S6K2 has a related function. Nevertheless, knockout studies for S6K1 showed that, while a certain degree of functional overlap exists between the two isoforms, with respect to their role in the regulation of protein synthesis, they do not entirely substitute each other (Shima et al., 1998) . The MEK/ERK pathway is known to regulate mRNA translation through Mnk1 (Waskiewicz et al., 1999) , but the potential involvement of S6K2 as an eector of MEK in translational regulation now requires urgent investigation.
In summary, our results suggest that while the development of selective S6K1 inhibitors might be of great therapeutic interest in SCLC treatment, speci®c inhibition of S6K2 might provide ways to modulate the MEK-dependent cellular response to growth factors.
Materials and methods
Cell culture
SCLC cell lines H-510, H-69, HC-33, H-209, H-524, H1045, H-1622, H-2171 were purchased from the American Type Culture Collection or were generously provided by Dr Adi Gazdar. Stocks were maintained in RPMI 1640 supplemented with 10% foetal bovine serum (heat inactivated at 578C for 1 h) in a humidi®ed atmosphere of 5% CO 2 /95% air at 378C. For experimental purposes, the cells were grown in serum free medium (SFM=RPMI 1640 supplemented with 5 mg/ml insulin, 10 mg/ml transferrin, 30 nM sodium selenite, 0.25% bovine serum albumin) and used between 3 and 7 days following transfer to this medium.
Clonogenic assays
SCLC cells, 5 ± 7 days post passage into SFM, were washed and resuspended in SFM. Cells were then disaggregated into a single-cell suspension by two passes through a 19 G needle and then through a 20 mm nylon gauze. 10 4 viable cells were mixed with SFM containing 0.3% agarose with or without FGF-2 and/or additional agents, and layered over a solid base of 0.5% agarose in SFM containing the same factors and/or agents at the same concentration in 33 mm plastic dishes. The cultures were incubated in humidi®ed 5% CO 2 / 95% air at 378C for 21 days and then stained with the vital stain nitroblue tetrazolium. Colonies of 4120 mm diameter (16 cells) were counted using a microscope.
Liquid culture assays SCLC cells, 3 ± 5 days post passage into SFM, were washed and resuspended in SFM. Cells were then aliquoted in 24-well Falcon plates at a density of 1.5610 4 cells per ml SFM in the absence or presence of FGF-2 and/or inhibitors. After the relevant incubation time, the cell number was determined from a minimum of three wells per condition using a haemocytometer, after cell clumps were disaggregated by passing the cell suspension ®ve times through a 21 and subsequently 19 gauge needle.
FGFR1 Western blotting
SCLC cells 3 ± 5 days post passage into SFM and T47D breast cancer cells in RPMI 1640 containing 10% FCS for three days were washed four times in RPMI 1640 and 2610 6 cells were then lysed in 26SDS ± PAGE sample buer. Lysates were normalized for protein and analysed by SDS ± PAGE and Western blotting using a monoclonal anti-FGFR1 antibody prior to visualization by enhanced chemiluminescence (ECL).
FGFR1 transphosphorylation
SCLC cells in SFM were washed four times in RPMI 1640 and aliquots of 5610 6 cells were resuspended in this medium prior to incubation for 30 min at 378C. H-510 or H-69 cells were then stimulated with 0.1 or 1 ng/ml FGF-2, respectively, for 5 min at 378C and lysed at 48C in 1 ml of lysis buer (10 mM Tris/HCL, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 2 mM Na 3 VO 4 , 1% Triton X-100, 10 mg/ml aprotinin, 10 mg/ml leupeptin and 1 mM AEBSF, pH 7.6). FGFR1 was immunoprecipitated for 2 h using a monoclonal anti-FGFR1 antibody. Protein-A agarose beads (40 ml, 1 : 1 slurry) were added for the third hour. Immunoprecipitates were washed three times at 48C with lysis buer then twice in kinase buer (20 mM (2-hydoxyethyl)-1-piperazineethanesulphonic acid, 10 mM MnCl 2 , 0.05% Triton X-100, pH 7.4) before being resuspended in 30 ml of kinase buer. The kinase reaction was initiated by addition of 100 mCi/ml of [g 32 P]-ATP and left to proceed for 20 min at room temperature. The reaction was stopped by addition of 60 ml of 26sample buer prior to SDS ± PAGE and autoradiography.
ERK1/2 and MEK phosphorylation SCLC cells were washed three times in RPMI, aliquoted (2610 6 cells/condition) and left to rest for 30 min (378C, 5% CO 2 ). Cells were then incubated with or without increasing concentrations of rapamycin for 45 min prior to FGF-2 stimulation for various times and at varying concentrations. Stimulation with either 400 nM phorbol ester 2,13 dibutyrate (PDB) or 3 ng/ml stem cell factor (SCF) for 5 min was used as a positive control. Lysates were analysed by SDS ± PAGE and immunoblotted with either anti-biphosphospeci®c-ERK or anti-biphosphospeci®c-MEK antibody prior to enhanced chemiluminescence (ECL).
S6K immune-complex kinase assay
SCLC cells grown in SFM were washed three times in RPMI 1640, and aliquots of 2610 6 cells were incubated in this media for 30 min at 378C. The cells were then treated with various growth factors, lysed at 48C in 1 ml of lysis buer (LB=20 mM HEPES ± NaOH (pH 7.4), 150 mM NaCl, 1% (w/v) Triton X-100, 2 mM EDTA, 10 mM sodium¯uoride, 10% (w/v) glycerol, 1 mM dithiothreitol, 2 mM Na 3 VO 4 , 10 mM b-glycerophosphate and protease inhibitor mix (Sigma) supplemented with 10 mg/ml aprotinin and 10 mg/ml leupeptin) and clari®ed by centrifugation at for 10 min at 48C. Immunoprecipitation was performed for 2 h at 48C using either a polyclonal anti-S6K1 or a polyclonal anti-S6K2 antibody. Protein A-agarose beads (40 ml, 1 : 1 slurry) were added for a further 1 h at 48C. Immune complexes were washed twice in lysis buer and three times in kinase buer (20 mM (2-hydoxyethyl)-1-piperazineethanesulphonic acid, 10 mM MgCl 2 , 1 mM DTT, 10 mM b-glycerophosphate, pH 7.4). The kinase reaction was initiated by resuspending the beads in 25 ml of kinase buer supplemented with 100 mM ATP, 100 mCi/ml [g 32 P]-ATP, 200 mM microcystin LR and 1 mg/ml S6-peptide (RRRLSSLRA). The reaction was pursued at 308C for 10 min (linear assay conditions) and terminated on ice by the addition of 10 ml ice-cold 0.5% orthophosphoric acid. Samples were centrifuged and 30 ml of the supernatant were spotted onto P81 Whatman chromatography paper. Filters were washed four times for 5 min in 0.5% orthophosphoric acid, immersed in acetone and dried before Cherenkov counting. The average radioactivity of two blank samples containing protein A agarose beads (40 ml, 1 : 1 slurry), but no immune complex, was subtracted from the result of each sample. The speci®c activity of the [g 32 P]-ATP used was 900 ± 1200 c.p.m./p.mol.
S6K phosphorylation
H-510 and H-69 SCLC cells were washed three times in RPMI, aliquoted (2610 6 cells/condition) and left to rest for 30 min (378C, 5% CO 2 ) prior to 10 min stimulation with 0.1 and 1 ng/ml FGF-2, respectively. Cells were then lysed on ice with 1 ml LB (see above). Immunoprecipitation was performed for 2 h at 48C using either a polyclonal anti-S6K1 or anti-S6K2 antibody. Protein A-agarose beads (40 ml, 1 : 1 slurry) were added for a further 1 h at 48C. Immunoprecipitates were washed three times with 1 ml lysis buer, resuspended in SDS-sample buer and analysed by SDS ± PAGE. Immunoblotting was performed using polyclonal anti-phosphospeci®c S6K antibodies and ECL.
In vitro PI3-kinase assays H-510 cells in SFM were washed three times and resupended at 1610 7 in 1 ml RPMI 1640 prior to stimulation with 10% foetal bovine serum or 0.1 ng/ml FGF-2 for 5 min at 378C. The samples were then washed once in ice-cold PBS, and lysed for 20 min on ice in 2 ml of lysis buer (20 mM HEPES ± NaOH (pH 7.4), 150 mM NaCl, 1% (w/v) Triton X-100, 2 mM EDTA, 10 mM sodium¯uoride, 10% (w/v) glycerol, 1 mM phenylmethylsulfonyl¯uoride, 5 mM benzamidine, 1 mM N-tosyl-Llysine chloromethyl ketone, 20 mM leupeptin, 18 mM pepstatin, 20 mg/ml aprotinin, 1 mM dithiothreitol, 2 mM Na 3 VO 4 , 10 mM b-glycerophosphate). The lysates were centrifuged at 48C for 20 min, 15 0006g. The supernatant was collected and incubated for 2 h at 48C with constant rotation with a p85a monoclonal antibody or an irrelevant mouse IgG. Protein GSepharose CL-4B was then added and the incubation continued for 1 h at 48C with constant rotation. The immunoprecipitates were washed twice in lysis buer and once in TBS (50 mM TrisHCl (pH 7.4), 150 mM NaCl). PI3K activity was assayed by resuspending the immunoprecipitates in 25 ml of 26kinase buer (40 mM Tris-HCl (pH 7.4), 200 mM NaCl). Phosphoinositides stored in CHCl 3 /MeOH (1 : 1) (v/v) were dried, sonicated for 15 min in 50 mM Tris-HCl (pH 7.4), and added to the samples (0.2 mg/ml). The kinase reactions were initiated in 50 ml ®nal volume by the addition of 3.5 mM of MgCl 2 , 40 mM ATP and 10 mCi of [g 32 P]-ATP and pursued for 10 min at 378C. Reactions were stopped by addition of 100 ml of 1 N HCl and 200 ml of CHCl 3 /MeOH (1 : 1) (v/v). The organic phase was collected, re-extracted with 40 ml of MeOH, 1 N HCl (1 : 1) (v/v). The samples were then dried, resuspended in 30 ml of CHCl 3 /MeOH (1 : 1) (v/v) and spotted onto Silica Gel 60 TLC plates pretreated with 1% (w/v) oxalic acid, 1 mM EDTA, 40% MeOH (v/v) and baked for 15 min at 1108C. The plates were developed in propanol, 2 M acetic acid (65 : 35) (v/v) and the radiolabelled spots detected by autoradiography.
PKB phosphorylation
H-510 cells were washed three times in RPMI, aliquoted (2610 6 cells/condition) and left to rest for 30 min (378C, 5% CO 2 ). Cells were then incubated with or without wortmannin (100 mM) for 30 min prior to FGF-2 stimulation (0.1 ng/ml, 10 min).
Isolation of Type II pneumocytes
Human lung tissue was obtained following lobectomy for carcinoma of the lung and type II pneumocytes isolated as described previously (Witherden and Tetley, 2001) . Brie¯y, normal regions distal to the tumour were excised and lavaged with 0.15 M NaCl using a 20 ml syringe and 21 gauge needle, to remove alveolar macrophages and blood cells. The tissue was then in¯ated with 0.25% trypsin in HBSS and incubated for 45 min at 378C. The tissue was then chopped ®nely in the presence of normal calf serum. DNase (250 mg/ml HBSS) was added to the minced tissue suspension and shaken vigorously for 5 min at room temperature. The suspension was ®ltered through coarse and then ®ne grade mesh to yield single cells. The type II cell-enriched ®ltrate was centrifuged at 3006g for 10 min. Contaminating macrophages and ®broblasts were removed by adherence to tissue culture plastic for 1 h in serum free and then 10% serum, respectively, at 378C. The type II cell-enriched supernatant was centrifuged as before, the cell pellet suspended in 10% normal calf serum in low protein hybridoma media (Life Technologies) with antibiotics and plated out at one million cells/well of a Vitrogen-coated 24 well tissue culture plate. The cells were allowed to reach con¯uence (approx. 3 days) prior to study.
Reagents
Anti-biphosphospeci®c ERK1/2 antibody, SCF, RPMI medium and PBS were purchased from Sigma-Aldrich Company Ltd (Poole, Dorset, England). Foetal bovine serum was purchased from GIBCO BRL. Rapamycin was obtained from Calbiochem-Novabiochem Ltd (Beeston, Nottingham, UK). The anti-biphosphospeci®c MEK antibody, the MEK inhibitors PD098059 and U0126 were from New-England Biolabs Ltd (Hitchin, Hertfordshire, UK). Lamin B and betaactin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PKB and phospho-PKB antibodies were raised by immunizing rabbits with synthetic peptides corresponding to the carboxy terminus of PKBa (RPHFPQFSYSASGTA) and to the sequence around phosphoserine 473 in PKBa (HFPQF[pS]YSASS) and were a generous gift from Dr J Downward (ICRF, Lincolns Inn Field, London, UK). Antibodies to phosphothreonine 229 and 389 of S6K1 (equivalent to T228 and T388 in S6K2) were raised by immunizing rabbits with synthetic peptides corresponding to the sequences CGTVTH[pT]FCGTI and CVFLGFT[pT]YVAPS, respectively. Their speci®city was veri®ed by competition assays in the absence or presence of the corresponding phosphorylated and non-corresponding phosphorylated peptides (data not shown). Antibodies to S6K1 and S6K2 were raised by immunizing rabbits with synthetic peptides to the sequences CKQAFPMISKR-PEHLRMNL and CRPPSGTKKSKRGRGRPGR, respectively as previously described (Valovka et al., 1999) . The FGFR1 monoclonal antibody was raised against a COOHterminal peptide (Leu 807 ± Arg 822 of FGFR1) as previously described (Yiangou et al., 1997) . Protein-A agarose was from Boehringer Mannheim (Lewes, East Sussex, UK). Agarose was from SeaKem (Rockland, ME, USA). Human recombinant FGF-2, Protein G-Sepharose CL-4B, Redivue [g 32 P]-ATP and ECL reagents were from Amersham-Pharmacia (St Albans, Herts, UK). P81 chromatography paper was purchased from Whatman (Maidstone, Kent, UK).
